A phase III clinical study of EB-101 gene therapy for patients with Epidermolysis Bullosa.

Trial Profile

A phase III clinical study of EB-101 gene therapy for patients with Epidermolysis Bullosa.

Planning
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs EB 101 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Registrational; Therapeutic Use
  • Sponsors Abeona therapeutics
  • Most Recent Events

    • 21 Jul 2017 New trial record
    • 18 Jul 2017 According to an Abeona Therapeutics media release, company plans to commence this study in early 2018.
    • 18 Jul 2017 According to an Abeona Therapeutics media release, company received guidance from the US FDA to commence pivotal phase III trial for EB-101 gene therapy for patients with Epidermolysis Bullosa.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top